These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

892 related articles for article (PubMed ID: 18178835)

  • 1. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Chan C; He Y; Jiang S; Wu C; Jin DY; Yuen KY; Zhou Y; Zheng BJ
    Vaccine; 2008 Mar; 26(13):1644-51. PubMed ID: 18289745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.
    Shim BS; Stadler K; Nguyen HH; Yun CH; Kim DW; Chang J; Czerkinsky C; Song MK
    Virol J; 2012 Sep; 9():215. PubMed ID: 22995185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
    Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
    Ma C; Li Y; Wang L; Zhao G; Tao X; Tseng CT; Zhou Y; Du L; Jiang S
    Vaccine; 2014 Apr; 32(18):2100-8. PubMed ID: 24560617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of SARS virus vaccines.
    Zheng BJ; Du LY; Zhao GY; Lin YP; Sui HY; Chan C; Ma S; Guan Y; Yuen KY
    Hong Kong Med J; 2008 Aug; 14 Suppl 4():39-43. PubMed ID: 18708674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses.
    Huang J; Cao Y; Du J; Bu X; Ma R; Wu C
    Vaccine; 2007 Sep; 25(39-40):6981-91. PubMed ID: 17709158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
    Du L; Zhao G; Chan CC; Li L; He Y; Zhou Y; Zheng BJ; Jiang S
    Viral Immunol; 2010 Apr; 23(2):211-9. PubMed ID: 20374001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
    Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
    J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
    Bukreyev A; Lamirande EW; Buchholz UJ; Vogel LN; Elkins WR; St Claire M; Murphy BR; Subbarao K; Collins PL
    Lancet; 2004 Jun; 363(9427):2122-7. PubMed ID: 15220033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.
    Liu RY; Wu LZ; Huang BJ; Huang JL; Zhang YL; Ke ML; Wang JM; Tan WP; Zhang RH; Chen HK; Zeng YX; Huang W
    Virus Res; 2005 Sep; 112(1-2):24-31. PubMed ID: 16022898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.
    Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY
    Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.